International Cancer Conference Journal

, Volume 8, Issue 4, pp 185–189 | Cite as

Genomic characterization for familial cases with urothelial carcinoma

  • Tetsuya ShindoEmail author
  • Megumi Hirobe
  • Yasushi Adachi
  • Yasushi Sasaki
  • Takashi Tokino
  • Naoya Masumori
Case report


In this report, we present familial cases of urothelial carcinoma. To investigate the possibility of hereditary urothelial cancer, we performed semiconductor-based next-generation DNA sequencing. A woman in her 80s who had bladder and left ureteral cancer was hospitalized in Sapporo Shirakaba-dai Hospital due to consciousness disturbance. Radiographic evaluation revealed multiple liver metastases and she died 38 days later. Needle necropsy was done for a left ureteral tumor that continued to her bladder tumor and for liver metastases. At the same time, her son in his 60s, who also had muscle-invasive bladder cancer, was admitted to Sapporo Medical University Hospital and underwent neoadjuvant chemotherapy followed by laparoscopic radical cystectomy. DNA was isolated from both cancers and normal controls in each case and analyzed by massive parallel sequencing of 409 cancer-related genes using a targeted, multiplex PCR approach followed by semiconductor sequencing. Somatic mutations of KMT2C and KMT2D were detected in the mother’s tumor. Copy number gains of FGFR1, IkBKB, NFkB2, FGFR2, and FLT3 and copy number losses of IGF2R and TP53 were also found in her cancer. In her son’s tumor, somatic mutations of FGFR3 and EP300 were identified. Copy number gains of IkBKE/MAPK1/PARP1, EGFR, BRAF, IRS2, MAPK2K1, IGF1R, and ERBB2 and copy number loss of TP53 were also found in his cancer. There were no germline gene mutations related to familial urothelial carcinoma. Although somatic mutation of TP53 was a common feature, these cases with urothelial carcinoma might not be the result of a heredity syndrome.


Urothelial cancer Familial cancer Next-generation sequencing 



Bladder cancer


Non-muscle-invasive bladder cancer


Muscle-invasive bladder cancer






Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Informed consent

Written informed consent was obtained from the patients.


  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRefGoogle Scholar
  2. 2.
    Hampel H, Frankel WL, Martin E et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352:1851CrossRefGoogle Scholar
  3. 3.
    Barrow P, Khan M, Lalloo F et al (2013) Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br J Surg 100:1719CrossRefGoogle Scholar
  4. 4.
    Rouprêt M, Yates DR, Comperat E et al (2008) Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. Eur Urol 54:1226–1236CrossRefGoogle Scholar
  5. 5.
    Joost P, Therkildsen C, Dominguez-Valentin M, Jonsson M, Nilbert M (2015) Urinary tract cancer in Lynch syndrome; increased risk in carriers of MSH2 mutations. Urology 86(6):1212–1217CrossRefGoogle Scholar
  6. 6.
    Skeldon SC, Semotiuk K, Aronson M, Holter S, Gallinger S, Pollett A et al (2013) Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol 63(2):379–385CrossRefGoogle Scholar
  7. 7.
    Win A, Young J, Lindor N, Tucker K, Ahnen D, Young G et al (2012) Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 30(9):958–964CrossRefGoogle Scholar
  8. 8.
    Beukers W, Hercegovac A, Zwarthoff EC (2014) HRAS mutations in bladder cancer at an early age and the possible association with the Costello syndrome. Eur J Hum Genet 22(6):837–839CrossRefGoogle Scholar
  9. 9.
    Nakagaki T, Tamura M, Kobashi K, Omori A, Koyama R, Idogawa M, Ogi K, Hiratsuka H, Tokino T, Sasaki Y (2018) Targeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma. Tumour Biol 40(9):1010428318800180. CrossRefGoogle Scholar
  10. 10.
    Nakagaki T, Tamura M, Kobashi K, Koyama R, Fukushima H, Ohashi T, Idogawa M, Ogi K, Hiratsuka H, Tokino T, Sasaki Y (2017) Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing. Oncotarget 15(35):59113–59122. Google Scholar
  11. 11.
    Huang D, Matin SF, Lawrentschuk N, Roupret M (2018) Systematic review: an update on the spectrum of urological malignancies in Lynch Syndrome. Bladder Cancer 3:261–268CrossRefGoogle Scholar
  12. 12.
    Van der Post RS, Kiemeney LA, Ligtenberg MJL, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D, Schaap L, Kets CM, van Krieken JH, Hoogerbrugge N (2010) Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among msh2 mutation carriers. J Med Genet 47:464–470CrossRefGoogle Scholar
  13. 13.
    Hollande C, Colin P, de La Motte Rouge T, Audenet F, Yates DR, Phé V, Ouzzane A, Droupy S, Ruffion A, de La Taille A, Guy L, Cussenot O, Rozet F, Xylinas E, Zerbib M, Spano JP, Khayat D, Bitker MO, Rouprêt M (2014) Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. BJU Int 113:574–580CrossRefGoogle Scholar
  14. 14.
    Sung JY, Sun JM, Chang Jeong B, Seo S, Soo Jeon S, Moo Lee H, Yong Choi H, Young Kang S, Choi YL, Young Kwon G (2014) FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy. Urol Oncol 1:e23–e31Google Scholar
  15. 15.
    Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW (2016) Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. Ann Oncol 7:1311–1316CrossRefGoogle Scholar
  16. 16.
    Duex JE, Swain KE, Dancik GM, Paucek RD, Owens C, Churchill MEA, Theodorescu D (2018) Functional impact of chromatin remodeling gene mutations and predictive signature for therapeutic response in bladder cancer. Mol Cancer Res 1:69–77CrossRefGoogle Scholar
  17. 17.
    Olanoa AR, Bellmunta J, Rodrigob A, Álvarezb L, Terrádezb A, García-Foncillasb J, Laesc JF (2017) A case report demonstrating the potential clinical benefit of exhaustive molecular profiling in an aggressive muscle-invasive high-grade metastatic urothelial carcinoma. Case Rep Oncol. Google Scholar
  18. 18.
    Wei L, Youquan W, Shubo T, Qishuo R, Tian Z, Guo H, Zhuo L, Guowen L (2018) Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in bladder carcinoma and its association with patients’ clinical features. Med Sci Monit 24:7178–7185. CrossRefGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2019

Authors and Affiliations

  1. 1.Department of UrologySapporo Medical University School of MedicineSapporoJapan
  2. 2.Department of UrologySanjukai Urological HospitalSapporoJapan
  3. 3.Division of Gastroenterology, Department of Internal MedicineSapporo Shirakaba-dai HospitalSapporoJapan
  4. 4.Medical Genome Science, Research Institute for Frontier MedicineSapporo Medical University School of MedicineSapporoJapan

Personalised recommendations